andarix.com
About company
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Their clinical stage products target specific cancers at the molecular level, and their companion diagnostics identify the patients with the corresponding molecular signature who are the best candidates for therapy. Their products are based on their proprietary peptide targeted radionuclide technology which can image and subsequently kill cancer cells with directed radiotherapy. Three clinical trials with Tozaride (Re188-P2045) have been completed and Phase 2 studies are being planned. Their team, with more than 75 years combined experience, is committed to creating treatments that produce significant and improved outcomes for cancer patients.
